Multiple System Atrophy (MSA)
15
7
8
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (15)
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
Multiple System Atrophy Multidisciplinary Clinic
MSA-01 in Multiple System Atrophy
[18F]ACI-15916 PET in α-synucleinopathies
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
AI-Enhanced Optimization of Acute Levodopa Challenge Test
Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
Oligomeric Alpha-synuclein in Multiple System Atrophy
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients